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Abstract
Aims/hypothesis Weight reduction is fundamental for type 2 diabetes management and remission, but uncertainty exists over
which diet type is best to achieve and maintain weight loss. We evaluated dietary approaches for weight loss, and remission, in
people with type 2 diabetes to inform practice and clinical guidelines.
Methods First, we conducted a systematic review of published meta-analyses of RCTs of weight-loss diets. We searched
MEDLINE (Ovid), PubMed,Web of Science and Cochrane Database of Systematic Reviews, up to 7May 2021.We synthesised
weight loss findings stratified by diet types and assessed meta-analyses quality with A Measurement Tool to Assess Systematic
Reviews (AMSTAR) 2. We assessed certainty of pooled results of each meta-analysis using Grading of Recommendations,
Assessment, Development and Evaluations (GRADE) (PROSPERO CRD42020169258). Second, we conducted a systematic
review of any intervention studies reporting type 2 diabetes remission with weight-loss diets, in MEDLINE (via PubMed),
Embase and Cochrane Central Register of Controlled Trials, up to 10 May 2021. Findings were synthesised by diet type and
study quality (Cochrane Risk of Bias tool 2.0 and Risk Of Bias In Non-randomised Studies – of Interventions [ROBINS-I]), with
GRADE applied (PROSPERO CRD42020208878).
Results We identified 19 meta-analyses of weight-loss diets, involving 2–23 primary trials (n = 100–1587), published 2013–
2021. Twelve were ‘critically low’ or ‘low’ AMSTAR 2 quality, with seven ‘high’ quality. Greatest weight loss was reported
with very low energy diets, 1.7–2.1MJ/day (400–500 kcal) for 8–12weeks (high-qualitymeta-analysis, GRADE low), achieving
6.6 kg (95% CI −9.5, −3.7) greater weight loss than low-energy diets (4.2–6.3 MJ/day [1000–1500 kcal]). Formula meal
replacements (high quality, GRADE moderate) achieved 2.4 kg (95% CI −3.3, −1.4) greater weight loss over 12–52 weeks.
Low-carbohydrate diets were no better for weight loss than higher-carbohydrate/low-fat diets (high quality, GRADE high). High-
protein, Mediterranean, high-monounsaturated-fatty-acid, vegetarian and low-glycaemic-index diets all achieved minimal (0.3–
2 kg) or no difference from control diets (low to critically low quality, GRADE very low/moderate). For type 2 diabetes
remission, of 373 records, 16 met inclusion criteria. Remissions at 1 year were reported for a median 54% of participants in
RCTs including initial low-energy total diet replacement (low-risk-of-bias study, GRADE high), and 11% and 15% for meal
replacements and Mediterranean diets, respectively (some concerns for risk of bias in studies, GRADE moderate/low). For
ketogenic/very low-carbohydrate and very low-energy food-based diets, the evidence for remission (20% and 22%, respectively)
has serious and critical risk of bias, and GRADE certainty is very low.
Conclusions/interpretation Published meta-analyses of hypocaloric diets for weight management in people with type 2 diabetes
do not support any particular macronutrient profile or style over others. Very low energy diets and formula meal replacement
appear the most effective approaches, generally providing less energy than self-administered food-based diets. Programmes
including a hypocaloric formula ‘total diet replacement’ induction phase were most effective for type 2 diabetes remission. Most
of the evidence is restricted to 1 year or less. Well-conducted research is needed to assess longer-term impacts on weight,
glycaemic control, clinical outcomes and diabetes complications.
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mike.lean@glasgow.ac.uk
Extended author information available on the last page of the article
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Abbreviations
AMSTAR A Measurement Tool to Assess Systematic
Reviews
DiRECT Diabetes Remission Clinical Trial
GRADE Grading of Recommendations, Assessment,
Development and Evaluations
ITT Intention to treat
LCD Low-carbohydrate diet
LFD Low-fat diet
MUFA Monounsaturated fatty acid
NRS Non-randomised study
VLED Very low energy diet
WMD Weight mean difference
Introduction
Type 2 diabetes has both environmental and genetic contribu-
tors, the global epidemic consistently following obesity. Its onset
is primarily driven by weight gain to an excessive level for that
individual, in a complex disease process involving gut
hormones, low-grade inflammation and metabolites, possibly
including some from the gut microbiota [1]. Ectopic fat accumu-
lation in liver, pancreas and muscle impairs organ functions,
resulting in hyperglycaemia, commonly associated with hyper-
tension and dyslipidaemia [2, 3]. Type 2 diabetes requires life-
long management, but disabling and life-shortening complica-
tions occur despite treatment [4]. Without strategic commitment,
internationally, to effective preventive actions, type 2 diabetes
will affect 629 million people worldwide by 2045 [5].
Weight loss improves all weight-related risk factors and
reduces medication load. During an intensive weight loss
programme, or early after bariatric surgery, there are already
significant improvements in hepatic and muscle insulin sensi-
tivity, and pancreatic first-phase insulin secretion, with rapid
loss of ectopic fat from skeletal muscle and liver [2, 3, 6]. A
non-diabetic state can be restored for 2 years for 70–80% of
people with type 2 diabetes by interventions that maintain
over 10 kg weight loss (36/149, 24% of participants in the
Diabetes Remission Clinical Trial [DiRECT]) [7], which
sustains loss of ectopic fat, reversing the pathophysiology
and normalising pancreas morphology [8].
Awareness of the benefits of weight loss for type 2 diabetes
is high, but both patients and healthcare practitioners currently
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lack authoritative guidance over diets [9]. Current guidelines
state that various dietary strategies may be effective, and stress
personalising weight management, to take account of social
situations, but do not provide guidance over diet compositions
[9, 10]. Consequently, practice can be led by distorted
evidence and claims.
Adhering to any energy-reduced diet will inevitably gener-
ate and sustain weight loss, whether defined by restriction of
energy, of food groups or of specific nutrients, provided that
there is incomplete compensation in energy intake and expen-
diture. In practice, adherence and weight losses vary widely
within the same programme, and comparisons between diets
often appear to have conflicting results [11]. Metabolic diver-
sity in response to specific nutrient contents has been postu-
lated, but possibly overwhelmed or confounded by mixed
behavioural responses to dietary advice. Unless carefully
designed, some diets may achieve negative energy imbalance
but lack essential micronutrients [12, 13] or introduce adverse
health effects through other pathways [14–16]. Furthermore,
short-term results may not be sustained, potentially requiring
additional behavioural approaches for long-termmaintenance.
While different strategies may work better for some individ-
uals (or some practitioners) than others, there may be preferred
diet compositions to optimise weight control [17].
Guideline development has been difficult because system-
atic reviews and meta-analyses of diet types, themselves open
to bias, have appeared conflicting [11]. To resolve these
uncertainties and to inform clinical decision making and
guideline development as part of a programme of work to
update the EASD dietary recommendations, we conducted
an umbrella review, to collate and critically appraise all avail-
able systematic reviews with meta-analyses of dietary inter-
ventions for weight loss in people with type 2 diabetes. As
remission of diabetes is now an important goal for weight
management, we also conducted a new systematic review
and quality appraisal of published intervention studies of
non-surgical dietary approaches for type 2 diabetes remission.
Methods
Protocol and registration
This paper focuses on dietary strategies for weight loss and
type 2 diabetes remission and includes two systematic
reviews: (1) a systematic ‘umbrella review’ of published
meta-analyses of RCTs of diets for weight loss in people with
type 2 diabetes (PROSPERO CRD42020169258); (2) a
systematic review of any intervention studies which report
type 2 diabetes remission (PROSPERO CRD42020208878).
Our paper is written in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) 2020 [18] and the Synthesis Without Meta-
analysis in systematic reviews: reporting guideline [19].
Detailed methods of both systematic reviews are presented
in the electronic supplementary material (ESM) Methods and
summarised in Fig. 1. The search strategy is in ESM Table 1.
(1) Umbrella review of published meta-analyses
We searched MEDLINE (Ovid), PubMed, Web of Science
and Cochrane Database of Systematic Reviews, up to 7
May 2021, for eligible meta-analyses of RCTs of dietary
advice for weight loss.
Data synthesis Synthesised findings (weight loss and HbA1c)
from each meta-analysis included are grouped by diet type,
ranked by overall methodological quality using A
Measurement Tool to Assess Systematic Reviews
(AMSTAR) 2 (ESM Tables 2, 3) and categorised into four
levels: high, moderate, low and critically low. Grading of
Recommendations, Assessment, Development and
Evaluations (GRADE) evaluates the certainty of evidence of
pooled results (ESM Table 4).
Planned analysis of associations between changes in ener-
gy intake and weight changes from baseline, to differentiate
effects of energy restriction and dietary regimen, proved
impossible from the published information.
(2) Systematic review of diets for type 2 diabetes
remission
We searched MEDLINE (via PubMed), Embase and
Cochrane Central Register of Controlled Trials, up to 10
May 2021, for any intervention studies reporting type 2 diabe-
tes remission with weight loss dietary advice. We first includ-
ed RCTs reporting type 2 diabetes remission as the primary
outcome, the design most likely to provide trustworthy
evidence. However, as few such RCTs have been conducted,
we also evaluated non-randomised studies (NRSs) to capture
the totality of the evidence for ‘best available advice’ to
inform practice and policy [20]. Cochrane Risk of Bias tool
2.0 [21] and Risk Of Bias In Non-randomised Studies – of
Interventions (ROBINS-I) [22] were used for quality assess-
ment of RCTs and NRSs, respectively.
Data synthesis Remission of diabetes was reported as percent-
age from intention to treat (ITT), including all participants. If
only completers were reported, we computed an ITT figure
assuming participants lost to follow-up all failed to achieve
remission (as in the published RCTs). We summarised effect
estimates (e.g., median and interquartile ranges), without
performing meta-analysis, due to the limited number and
heterogeneity of studies [23]. GRADE assesses the certainty
of synthesised findings [24].
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For the main synthesis, priority was set to RCTs
reporting 1 year outcome and low risk of bias. If there
was no RCT for a particular diet, synthesis findings
were drawn from NRSs with low, followed by high,
risk of bias. If both RCTs and NRSs were available
for a diet, RCTs were used for synthesised findings
and NRSs as supportive evidence [20]. Heterogeneity
was explored according to hypothesised effect modi-
fiers: study design, duration of type 2 diabetes and
ethnicity.
Results
(1) Umbrella review of published meta-analyses of
RCTs of diets for weight loss and glycaemic control
Identification of meta-analyses We retrieved 1064 records,
including all languages. After removing duplicates, we
screened 690 titles and abstracts, and assessed 59 full texts
for eligibility. Excluded full texts, with reasons, are shown
in ESM Table 5. We included a total of 21 systematic reviews
Umbrella review of diets for weight loss Systematic review of diets for T2D remission
Eligibility criteria
i. Systematic reviews with meta-analyses of 
RCTs
ii. Compared any type of diets with any control 
diet or usual/routine care
iii. Adult participants, either sex, with T2D
iv. Provided pooled results on a weight loss 
outcome (primary outcome) and/or changes in 
HbA1c (secondary) as mean difference between 
the two diet interventions, or mean difference 
from baseline, at any length of follow-up
v. Papers were excluded if the diet intervention 
(or comparators) included additional 
components (e.g., drugs, bariatric surgery, 
exercise, or education)
Search and information source
Databases (inception to 4 February 2020, updated 07 
May 2021)
 Medline (OvidSP) 
 PubMed
 Web of Science Core Collection
 Cochrane Database of Systematic Reviews
Free text & Mesh terms: diet, weight loss or weight 
reduction, type 2 diabetes, and meta-analysis. 
Reference lists of included reviews were also 
searched. Neither search restrictions nor limits were 
applied. A full search strategy for Medline is available 
in ESM Table 1
Search and information source
Databases (inception to 4 August 2020, updated 10 
May 2021)
 Medline (PubMed)
 Embase (OvidSP) 
 Cochrane Trial Registry (CENTRAL)
Free texts & MeSH terms: type 2 diabetes, remission, 
diet, and intensive lifestyle intervention were used, with 
Boolean NOT for surgery or bypass in titles and 
abstracts.  Reference lists of included reviews were 
also searched.  Neither search restrictions nor limits 
were applied. A full search strategy for Embase is 
available in ESM Table 1
Data extracted from included studies: 
authors, year, title, population characteristics including 
T2D duration, diet interventions, duration of diets, 
definition of T2D remission, percentage of remission, 
amount of weight loss, methods of analysis (whether 
ITT or completer analysis), dropout and funding 
agency 
Methodological quality assessment
AMSTAR 2b: assess methodological quality (internal 
validity) of included meta-analyses (ESM Tables 2 and 
3)
Certainty of evidence assessment
GRADE system: rate the certainty of evidence for 
pooled results from included meta-analyses
Methodological quality assessment
Cochrane Risk of Bias tool version 2.0: assess 
methodological quality (internal validity) of included 
RCTs [21] (ESM Fig. 3)
ROBIN-I: assess methodological quality (internal 
validity) of included NRSs [22] (ESM Table 17)
Certainty of evidence assessment
GRADE system: rate the certainty of evidence for 
synthesised evidence from included studies
Data extracted from included meta-analyses: 
authors, year, title, population characteristics, 
definitions of diet interventions and controls, numbers 
of included trials and numbers of total participants from 
each meta-analysis, duration of study, pooled results 
on amount of weight loss and HbA1c and 95% CI, I2
heterogeneity statistic and its p value, publication bias,
GRADE recommendation (if available)
Eligibility criteria
i. RCTs comparing any type of diet with any 
control diet or usual/routine care, using either 
food-based or formula diets
ii. NRSsa as following: (1) non-RCTs; and (2) 
single arm intervention without control group of 
any type of diets
iii. Reported proportion/percentage/rate of T2D 
remission after dietary intervention
iv. Studies were excluded if:
 diet intervention (or comparators) 
included additional components (e.g., 
drugs, bariatric surgery, exercise or 
education)
 observational studies of self-reported 
dieters, without intervention provided
Fig. 1 Summary of the
methodological processes of both
systematic reviews. Detailed
methods are presented in the ESM
Methods. aThese types of NRSs
provided intervention to
participants and assessed
outcomes at designated specific
time points (baseline and at the
end of intervention), although
they could suffer from selection
bias and confounding bias.




summary of the results of the
available studies that addresses
the question of interest;
moderate—the meta-analysis has
more than one weakness, but no
critical flaws. It may provide an
accurate summary of the results of
the available studies; low—the
meta-analysis has a critical flaw
and may not provide an accurate
and comprehensive summary of
the available studies that address
the question of interest; or
critically low—the meta-analysis
has more than one critical flaw
and should not be relied on to
provide an accurate and
comprehensive summary of the
available studies. CENTRAL,
Cochrane Central Register of
Controlled Trials; ROBINS-I,
Risk Of Bias In Non-randomised








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(with 19 meta-analyses) for data synthesis and quality assess-
ment (ESM Fig. 1).
Characteristics of included meta-analyses Of the 19 meta-
analyses (Table 1, ESM Table 6), 18 reported direct compar-
isons of specific diets. Control diets varied, either usual/
routine care or a particular dietary regimen. One meta-
analysis used a network method to consider both direct and
indirect comparisons between multiple diets (Mediterranean
diets, low-carbohydrate diets [LCDs], low-fat diets [LFDs],
high-carbohydrate diets and usual diets) [25]. Most meta-
analyses were of critically low (n = 7; [25–31]) to low quality
(n = 5; [32–36]). Only seven meta-analyses (LCDs, n = 5
[37–40, 41]; liquid meal replacement, n = 1 [42]; very low
energy diet (VLED), n = 1 [43]) were assessed as high qual-
ity. The ESM Results and ESM Tables 7–10 present method-
ological quality, heterogeneity and overlaps in source trials of
meta-analyses included in the umbrella review.
Dietary advice for weight loss Weight loss outcomes from
published meta-analyses are presented in Figs. 2, 3 and ESM
Table 11.
LCDs Ten meta-analyses reported on LCDs compared with
higher-carbohydrate diets. Not all reported whether source
RCTs were ad libitum or hypocaloric prescriptions, with
results often pooled from both trial types. Definitions of
LCDs varied, including <130 g/day, and <26% or <45% of
energy intake from carbohydrate. Duration of interventions
ranged from 8 weeks to 4 years.
Four high-quality meta-analyses [37–40] reported that
LCDs and higher-carbohydrate diets were equally effective
for weight loss, with mean difference ranging between <1
and <2.5 kg, at all durations. GRADE assessment ranged from
low to high certainty of evidence. Just one meta-analysis
reported greater weight loss with LCD, by 3.5 kg, using
complete case data for pooled results [41]. The remaining
critically low- to low-quality meta-analyses showed differ-
ences of <1 kg between the two diets [26, 27, 31, 33, 34].
Very low-carbohydrate diets (21–70 g of carbohydrate
daily) showed no greater weight loss than higher-
carbohydrate diets over durations of 3–36 months (weight
mean difference [WMD] −0.7 kg; 95% CI −2.0, 0.7; I2 =
46%, p = 0.10) in a subgroup analysis [37]. A subgroup ana-
lysis of RCTs with low risk of bias reported no difference
(WMD 0.9 kg; 95% CI -1.9, 3.6), while RCTs with high risk
of bias showed greater weight loss for LCDs than higher-
carbohydrate diets (WMD −1.8 kg; 95% CI −2.8, −0.7) [37].
High-protein diets All meta-analyses (n = 3) of high-protein
diets were of critically low quality [26, 28, 30]. Critical
domains unmet were presence of a review protocol and
assessing risk of bias in synthesised findings (ESM Table 3).
Only one provided a definition of ‘high protein’ (>20% of
energy intake), reporting significantly greater weight loss
(−1.2 kg; 95% CI −2.17, −0.24; I2 = 5%, p = 0.38) than with
lower-protein diets (<20% of energy from protein) [28].
Mediterranean diets Twometa-analyses, of low and critically
low quality, considered weight loss from Mediterranean diets
[26, 32]. The control interventions combined no diet (usual
care) and specified diets, including LFD and LCD. Pooled
results indicated significantly greater weight loss with
Mediterranean diets than in control groups, by 0.3 kg (low
quality; [32]) to 1.8 kg (critically low quality; [26]), over
durations of 4–24 weeks. A network meta-analysis also
reported that Mediterranean diets were marginally more effec-
tive than LFDs for weight loss (−1.2 kg; 95%CI −1.99, −0.37;
four RCTs, low quality; p-heterogeneity = 0.08; ESM
Table 12) [25].
Formula meal replacement One high-quality meta-analysis
[42] of nine RCTs including 931 participants reported that
replacing one to three main meals daily (replacing 13–47%
of total energy) produced significantly greater weight loss
than low-energy diets over 12–52 weeks (−2.4 kg; 95% CI
−3.3, −1.4; I2 = 84%, p < 0.001; GRADE moderate certainty
of evidence).
VLEDs One high-quality meta-analysis [43] of two RCTs
reported that VLEDs (1.7–2.1 MJ/day for 8–12 weeks)
achieved greater weight loss at 3 months (−6.6 kg; 95% CI
−9.5, −3.7; I2 = 58%, p = 0.12) and at 6 months (−5.7 kg;
95% CI −11.1, −0.4; I2 = 58%, p = 0.12), compared with an
energy-restricted diet (4.2–6.3 MJ/day). These data were from
participants who completed the trials.
High-monounsaturated-fatty-acid, vegetarian and low-
glycaemic-index diets High-monounsaturated-fatty-acid
(MUFA) [29] and vegetarian diets [35] showed greater weight
losses, by −1.6 to −2 kg, than the control diets. Low-
glycaemic-index diets [26, 36] were not associated with great-
er weight loss than control diets. Published meta-analyses of
these diets were of low to critically low quality.
Intermittent fastingWe did a post hoc analysis to evalu-
ate all systematic reviews without meta-analyses (no
pooled weight loss; n = 10) that were excluded from
our main analysis (as intended protocol). Eight were
systematic reviews whose source RCTs were already
pooled in meta-analyses identified in this umbrella
review. The remaining two systematic reviews compared
altered eating patterns with conventional energy-
restricted diets (ESM Table 13) [44, 45]. From these
two reviews, three RCTs were identified: two for 5:2
diets reported no difference in weight loss (high-risk-
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of-bias RCTs) [46, 47], and one for time-restricted
dieting reported 1.4 kg greater weight loss than conven-
tional energy restriction (high-risk-of-bias RCT) [48].
Adherence Some meta-analyses offered assessed dietary
adherence separately from weight change. Adherence
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4−15 months
4 weeks to 2 years
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High-protein diet
Qian et al, 2016 [29]
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Huo et al, 2015 [32]
Ajala et al, 2013 [26]
Mediterranean diet
Zafar et al, 2019 [36]
Ajala et al, 2013 [26]
Low-glycaemic-index diet
Viguiliouk et al, 2019 [35]
Vegetarian diet
Goldenberg et al, 2021 [41]
Korsmo-Haugen et al,
2019 [37]
van Zuuren et al, 2018 [38]
Sainsbury et al, 2018 [39]
Naude et al, 2014 [40]
McArdle et al, 2019 (1) [34]
McArdle et al, 2019 (2) [34]
Meng et al, 2017 [33]
Snorgaard et al, 2017 [31]
Fan et al, 2016 [27]
Ajala et al, 2013 [26]
LCD
Noronha et al, 2019 [42]
Formula meal replacement















































































Fig. 2 All published meta-analyses of intervention diets vs control diets
on weight loss (kg) stratified by overall quality in each diet type using
AMSTAR 2 quality (green, high quality; orange, low quality; red, criti-
cally low quality). WMDs are presented alongside 95% CIs (error bars).
Pooled results of McArdle et al., 2019 [34], Fan et al., 2016 [27], Zafar
et al., 2019 [36] and Zhao et al., 2018 [30] are standardised mean differ-
ences. aComplete case data. GRADE level for certainty of evidence is
rated as follows: ‘high’ indicates that we are very confident that the true
effect lies close to that of the estimate of the effect; ‘moderate’ indicates
that we are moderately confident in the effect estimate (the true effect is
likely to be close to the estimate of the effect, but there is a possibility that
it is substantially different); ‘low’ indicates that our confidence in the
effect estimate is limited (the true effect may be substantially different
from the estimate of the effect); and ‘very low’ indicates that we have
very little confidence in the effect estimate (the true effect is likely to be
substantially different from the estimate of effect)
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carbohydrate diets (<50 g of carbohydrate) than with LCDs
(<130 g of carbohydrate) [34, 37, 40], possibly because most
of the trials allowed increased carbohydrate intake for later
weight loss maintenance. High adherence to VLEDs (up to
6 months), judged from rapid early weight loss and dietary
assessment, led to better long-term results [43].
Effects of weight-loss diet intervention on HbA1c Among
published meta-analyses, HbA1c reduction broadly followed
weight loss, and differences between diet types assessed over
3–12 months were small. The published data do not permit an
individual-level regression analysis to quantify weight loss-
independent effects on HbA1c (ESM Results, ESM Table 14).
(2) Systematic review of intervention studies (either
RCTs or NRSs) of diets for remission of type 2 diabetes
Identification of studies From 373 records identified, we
included 16 papers for data synthesis and quality assessment
(ESM Fig. 2; excluded studies with reasons in ESM Table 5).
These reported on 14 studies (six RCTs, eight NRSs), of seven
diet types: total diet replacement (n = 4), formula meal
replacement (n = 2), VLED (n = 2), very low-carbohydrate
ketogenic diet (n = 1), Mediterranean diet (n = 2), LFD (n =
4) and the ADA diet (n = 1). Five studies compared diet
interventions with usual care according to clinical guidelines,
without providing foods or dietary products for participants
[49–53]. Among these, three provided diabetes education or
advice (Table 2) [49, 50, 52]. Included studies were conducted
in Barbados, India, Italy, Qatar, South Africa, Spain,
Thailand, the UK and the USA. Detailed characteristics and
methodological quality are in the ESM Results, ESM
Tables 15–17 and ESM Fig. 3.
Definition of type 2 diabetes remission All included studies
defined remission as a diagnostic test result, without glucose-
lowering medication, below the WHO threshold for diagnosis
of type 2 diabetes (HbA1c < 48 mmol/mol [6.5%], or fasting
plasma glucose <7 mmol/l), but they differed in the duration
prior to assessment of remission (ESM Tables 15–16). Some
studies [54–57] subdivided results as previously proposed by
Buse et al. [58]. Glucose-lowering medications were not
routinely withdrawn at the beginning of diets in some of the
studies, so only minimum remissions can be reported.
Effects of diets on type 2 diabetes remission and weight at
1 year Remission rates and weight changes at 1 year are
summarised in Fig. 4 and Table 2, with GRADE certainty of
evidence in Table 3.
Programmes that included an induction phase of formula
‘total diet replacement’ were studied in two RCTs with low
risks of bias. Compared with remissions of 4–12% in well-
matched usual care control arms, the interventions generated
median 54% remission at 12 months from baseline (N = 445,
two RCTs; GRADE high certainty of evidence), with diabetes
durations <6 or <2 years, and mean weight loss of 10 and
12 kg. These two RCTs were designed with remission as the
primary outcome [51, 53].
Among trials reporting post hoc analyses for remission,
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WMD (kg)
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Fig. 3 Meta-analyses with source RCTs of 12 months or longer on
weight loss (kg) outcome.WMDs are presented alongside 95%CIs (error
bars). Different colours indicate meta-analysis quality: green, high qual-
ity; red, critically low quality. GRADE level for certainty of evidence:
‘high’ indicates that we are very confident that the true effect lies close to
that of the estimate of the effect; ‘moderate’ indicates that we are moder-
ately confident in the effect estimate (the true effect is likely to be close to
the estimate of the effect, but there is a possibility that it is substantially
different); ‘low’ indicates that our confidence in the effect estimate is
limited (the true effect may be substantially different from the estimate
of the effect); and ‘very low’ indicates that we have very little confidence
in the effect estimate (the true effect is likely to be substantially different
from the estimate of effect)
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and one per day thereafter reported 11% (247/2157) remission
at 1 year (prevalence estimates), with meanweight loss 8.6 kg,
compared with 2% (43/2170) in standard care (N = 4503;
GRADE low certainty of evidence), with some concern over
risk of bias [49].
A single RCT ofMediterranean diet over 12months report-
ed a remission prevalence of 15% (15/102), with mean weight
loss 6.2 kg, compared with 4% (4/97) with weight loss 4.2 kg
in the control LFD arm (N = 215; GRADE low certainty of
evidence; some concern over risk of bias) [59].
No RCT has evaluated LCDs/ketogenic diets for type 2
diabetes remission. A non-randomised, controlled study of a
very low-carbohydrate (ketogenic) diet reported 20% remis-
sion (52 out of 262 who started treatment [ITT] who had
HbA1c < 48 mmol/mol [6.5%] without diabetes medication),
with mean weight loss 13.8 kg, at 1 year, compared with no
remission in a control arm (N = 349; GRADE very low
certainty of evidence; serious risk of bias) [50]. The dropout
rate was 17% (44/262) and 22% had incomplete outcome
data. This study primarily focused on HbA1c lowering, not
remission, so glucose-lowering medications were not routine-
ly withdrawn.
Another very small uncontrolled study evaluated a 1 week
2.9 MJ/day (700 kcal) food-based diet, finding 22% (2/9)
remission at 1 year, with mean weight loss 4.2 kg (N = 9,
one single-arm intervention; GRADE very low certainty of
evidence; critical risk of bias) [60].
Sources of heterogeneity Single-arm intervention studies
reported higher remission than RCTs. Participants with
shorter type 2 diabetes duration, and Asian ethnicity, were
more likely to achieve remission than those with longer type
2 diabetes duration or another ethnicity (Table 2, ESM
Tables 15,16).
Discussion
Dietary weight reduction for people with type 2
diabetes
This study was conducted to inform practice and policy over
dietary advice for weight management of people with type 2
diabetes. It has therefore focused on interventions in free-
living individuals, with a view to long-term management.
Based on methodological quality and certainty of the
evidence, our umbrella review of meta-analyses found that
VLEDs and formula meal replacements produce greater
weight losses than conventional low-energy diets. The
evidence does not favour LCDs above higher-carbohydrate
diets, nor other dietary approaches, i.e., high-protein,
Mediterranean, high-MUFA, vegetarian and low-glycaemic-
index diets, above control diets. Currently popular intermittent
fasting was only captured in systematic reviews without meta-
analysis (high-risk-of-bias RCTs) [44, 45]. The evidence,
albeit of variable ‘quality’, is rather consistent such that no
one diet type is superior over others for weight management
in type 2 diabetes.
While the evidence does not suggest important differences
between macronutrient compositions in effectiveness, there
may be differences in cost-effectiveness. The evidence on
relative cost-effectiveness of weight-loss diet programmes is
limited from head-to-head diet comparison trials, but one RCT
showed that LCD was not more cost-effective than the stan-
dard weight-loss diet [61]. In the Doctor Referral of
Overweight People to Low Energy total diet replacement
Treatment (DROPLET) trial among people without diabetes,
in routine practice, a total diet replacement programme
(formula diets) with behavioural support proved more cost-
effective than nurse-led dietary advice for long-term preven-
tion of obesity-related diseases [62]. For diabetes remission, a
total diet replacement programme was estimated to be both
more cost-effective and cost-saving than standard care in the
DiRECT trial, reflecting reduced need for medications and
fewer diabetes complications [63].
Health benefits from weight management depend largely
on long-term control of body weight. Most of the evidence
cited relates to short-term outcomes, relevant to the initial
weight loss induction phase of weight management. Few trials
have reported data beyond 12 months, to reflect weight loss
maintenance, which may demand different behavioural strat-
egies. One large RCT of high-protein diet suggested benefit
for weight loss maintenance, increasing satiety and energy
expenditure, albeit for a maintenance phase of only 6 months
after completing weight loss [64]. Nutrient-specific effects
have been postulated, but are likely to be overwhelmed by
variable behavioural responses to dietary advice [65].
Behavioural programmes help to sustain new behaviours,
relationships with foods and adherence to dietary advice
[66–68]. Consistent evidence is also accruing that long-term
weight loss maintenance is better after more rapid early weight
loss [69]. Thus, treatments effective for weight loss only in the
short term may have long-term value if complemented with a
good weight loss maintenance strategy. Practitioners can
therefore be confident that a variety of diet types can all
achieve the intended weight losses, and potentially remissions
of type 2 diabetes, if their patients are able to adhere to the
programme sufficiently.
The analyses contradict some popular claims about specific
diets: in particular, ‘low-carb’ diets hold no overall advantage
for weight loss when compared with higher-carbohydrate
diets. However, we cannot conclude that any individual with
type 2 diabetes, in any context, will do equally well with any
diet advice, or that a skilled practitioner may not have greater
success advising one diet type. The skills and empathy of
practitioners may overcome any diet-specific effects on
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weight loss by providing consistent evidence-based support
[70]. Realistic trials are required, in which individuals are
offered choices, perhaps using n = 1 randomised trial designs.
Weighing benefits against risks
Food is fundamental for personal and social wellbeing, and
diets can be psychologically testing. Patient preferences,
culture, context and lifestyle demand open conversation and
shared decision making between practitioners and patients.
For either medication or diet, weighing benefits against risks
is vital: treatment benefits are often overestimated but harms
underestimated [71]. Although all diet types are similarly
effective for weight control, health risks were not systemati-
cally reported across the studies, and could differ [72]. More
rapid early weight loss with more intensive programmes is
associated with better longer-term weight outcomes [69], but
severe caloric restriction without attention to nutrient content
can have unwanted effects. Blood pressure falls with weight
loss, and postural hypotension, common in older people and
those with diabetes, is aggravated during rapid weight loss if
diuretic or antihypertensive drugs are taken concurrently [73].
Hypoglycaemia is possible if hypoglycaemic drugs are also
taken [74]. Diets other than nutritionally complete formula
diets could incur vitamin and mineral deficiencies [75]. With
ketogenic diets, heart failure and neurological problems from
thiamine deficiency have been reported [76, 77], as well as
reduced intakes of folate, iron and magnesium [12]. Replacing
high-carbohydrate foods with red or processed meat (high
animal protein and fat) increases sodium and long-chain satu-
rated fat intakes, elevating LDL-cholesterol [15, 16] and
potentially increasing cardiovascular disease risk [78–80].
High protein intake has been associated with kidney diseases
in several observational studies [81]. Metabolic ketoacidosis
with ketogenic diets is a hazard, particularly with sodium
−glucose cotransporter 2 (SGLT2) inhibitors [82–87].
Meanwhile, extreme fat avoidance provokes cholelithiasis [88].
Remission of type 2 diabetes
Current evidence on diets for type 2 diabetes remission is
more limited. Only two RCTs had remission as the pre-
specified outcome, both relatively large and using almost
identical designs and diets, with very similar results, but in
very different populations, notably with different durations
of diabetes [51, 53, 89]. A large majority can achieve remis-
sion if they maintain sufficient weight loss.
NRSs (non-RCT, single-arm intervention) reported remis-
sion rates ranging from 3% to 75% by ITT, over various
follow-up durations. The highest remission rates, up to 75%,
were in people with newly diagnosed diabetes orwith <2 years
of type 2 diabetes duration. Much lower 20–22% remissions
were reported with longer type 2 diabetes duration (8 years) or
a very brief diet period (1 week). However, these studies did
not all fully ascertain remission status, and they had critical
risks of bias due to lack of comparator groups and/or
randomisation. NRSs reflect performance among those who
select and can adhere to a particular diet, and so usually report-
ed better results than those featuring random assignment. In
some cases, remission rates were reported for completers only,
rather than using the ITT population to properly guide
healthcare practice and policy. Despite extracting baseline
data for ITT analysis, residual bias/confounding may remain
with these study designs.
The main contributor to HbA1c reduction and remission
appears to be weight loss, irrespective of diet type. From the
high-quality studies with high GRADE certainty, structured
programmes with an intensive induction phase with total diet
replacement were effective. Remission of diabetes occurs
when a patient no longer satisfies the diagnostic criteria, with-
out receiving glucose-lowering medication. To ascertain
remission for those already prescribed glucose-lowering
drugs, a therapeutic trial of withdrawing medication is neces-
sary, with an appropriate protocol for re-introduction if neces-
sary. Confirmation over a defined duration (e.g., 6 or
12 months) will be required for re-classifying individuals,
and for legal or insurance purposes. The diagnostic HbA1c
cut-off for diabetes of 48 mmol/mol (6.5%) was defined by
WHO as broadly the level where diabetes-specific microvas-
cular complications start to emerge [90, 91]. However, many
people in remission from type 2 diabetes remain in the pre-
diabetes range of HbA1c, where cardiovascular disease risk
begins to rise [92, 93]. Lowering HbA1c to very low levels
with multiple medications among people with longstanding
disease is associated with increased mortality rate, possibly
by relative hypoglycaemia provoking arrythmias [94]. No
such concerns have been reported in the small numbers who
achieved and sustained HbA1c < 42 mmol/mol (<6.0%) from
diet restriction [89].
Most type 2 diabetes is treated in primary care, the setting
for both published remission trials using an intensive ‘total
diet replacement’ induction phase with formula diets [51].
Simpler food-based programmes may be effective. A service
evaluation from one UK general practice reported weight loss
and remission in 59 out of 128 patients who opted for, and
persisted with, LCD advice for a mean 23 months [95]. This
completers’ analysis omits information about numbers who
declined the diet, who started but failed to persist and who
did not provide outcome data at designated times. The LCD
was routinely offered since 2013, and the total number of
patients with type 2 diabetes was 473 at the time of evaluation,
so these data imply that 12.5% of the practice achieved remis-
sion [95]. A population-based cohort study from 49 general
practices in the UK (the Anglo–Danish–Dutch Study of
Intensive Treatment in People with Screen-Detected





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































867 participants with newly diagnosed type 2 diabetes; after
being followed up for 5 years, there was an overall 30% remis-
sion (n = 257/867; ITT analysis). Loss of >10% of baseline
body weight in the first year after diagnosis was associated
with 70% higher chance of remission at 5 years [96]. Every
1 kg of weight loss was associated with 7% higher chance of
remission at 5 years, regardless of specific diet regimens or
lifestyle interventions [96]. There is therefore consistent
evidence that remission should be attempted as early as possi-
ble from diabetes diagnosis [70, 96].
Limitations
AMSTAR 2 assesses the quality of meta-analyses, prioritising
critical domains, where errors and bias can impact pooled
findings (ESM Table 2). Only one or two flaws can label a
meta-analysis ‘low’ or ‘critically low’, with some criteria
potentially subjective (e.g., adequacy of the literature search;
ESM Table 2). In the umbrella review, many meta-analyses
were of ‘low’ and ‘critically low’ AMSTAR 2 quality,
predominantly through ‘no protocol reported’ (despite clear
and sound methods) and no assessment of publication bias.
Many meta-analyses had fewer than ten RCTs to permit
assessment of publication bias by funnel plot [97]. If
AMSTAR 2 criteria are relaxed for protocol reporting and
publication bias, the meta-analyses allow some confidence
in the consistent findings of little/no difference in weight loss
between any diets.
Although the search strategy was wide and not language-
restricted, most studies included European participants; results
Table 3 Summary of findings of type 2 diabetes remission at 1 year after diet intervention compared with baseline with GRADE certainty of a body of
evidence




Certainty in the evidencea Comments
TDR TDR leads to a large increase in T2D
remission by a median of 54% from
baseline (range 46–61%), when compared






outcomes with power calculation
Meal
replacement
Meal replacement likely leads to T2D
remission by 11% from baseline, when








Ancillary observational analysis of RCT
Mediterranean
diet
Mediterranean diet may lead to T2D
remission by 15% from baseline, when
compared with LFD (4%).
215 (1 RCT) ⊕⊕◯◯
LOW
Due to imprecisionb and
possible publication
bias
Small sample size, and ancillary





The evidence is very uncertain about the
effect of ketogenic diet on T2D remission
due to serious risk of bias of the study
methods and imprecision, although one
non-RCT reported a remission rate of
20%, compared with no remission in





Due to serious risk of bias
(rated down 2 levels)
and imprecisionb
Lack of randomisation, uncontrolled
confounding, selection bias, incomplete
outcome data, possible selective




The evidence is very uncertain about the
effect of food-based VLED on T2D
remission, although one small
uncontrolled intervention study reported a









Due to critical risk of bias




Lack of randomisation, uncontrolled
confounding, selection bias and selective
reporting of result. Only one positive,
small study
Remission is defined as either HbA1c < 48 mmol/mol (<6.5%) or fasting plasma glucose <7 mmol/l and no glucose-lowering medication
a GRADE level for certainty of evidence: ‘high’ indicates that we are very confident that the true effect lies close to that of the estimate of the effect;
‘moderate’ indicates that we are moderately confident in the effect estimate (the true effect is likely to be close to the estimate of the effect, but there is a
possibility that it is substantially different); ‘low’ indicates that our confidence in the effect estimate is limited (the true effect may be substantially
different from the estimate of the effect); and ‘very low’ indicates that we have very little confidence in the effect estimate (the true effect is likely to be
substantially different from the estimate of effect)
b Rated down one level due to imprecision, as the sample size is less than an optimal information size of 400
T2D, type 2 diabetes; TDR, total diet replacement
Diabetologia
may not be equally applicable to other ethnic and/or deprived
communities. South Asians develop type 2 diabetes at younger
ages, more rapidly and with lower BMI, so may be more sensi-
tive to weight loss, with physiological differences in insulin
resistance, body composition and fat oxidation [98, 99].
The criteria used in the reported meta-analyses and studies
focused on specific diet types. However, not all reported suffi-
cient detail about macronutrient or micronutrient contents, or
prescribed and reported energy intakes, including energy
intake of nutrient-restricted ad libitum diets, which limits
interpretation and transferability of results. Control diets used
in the meta-analyses and source RCTs also varied, including
‘usual’ diets in different countries, as well as specified dietary
regimens (Table 1). Despite this, differences in weight loss
between intervention and control diets, commonly 0–2 kg,
are of little clinical significance. Durations of interventions
varied: as weight regain is frequent over a longer period,
heterogeneity might be expected. However, duration did not
introduce heterogeneity, probably because trials with longer
follow-up tended to be evaluating more intensive interven-
tions with greater initial weight loss, such that the net weight
changes at endpoint are similar to short-term trials.
Given the extent of literature concluding that differences in
weight control or HbA1c from different diet compositions are
not clinically significant, future trials of similar diet compari-
sons are unlikely to add useful information. Instead, evidence
from clinical practice is needed to identify safe and effective
approaches to achieve and maintain weight loss with available
skills and training, to assess long-term outcomes from high-
quality trials and prospective audits of practice with different
diets. Interpretating the existing data might be enhanced through
individual patient data meta-analysis. Alternatively, the very
large amount of work entailed in conducting repeated meta-anal-
yses, and the limitations of different inclusion criteria and
detailed methods, support a prospective meta-analysis approach
[100, 101]. All primary studies for inclusion should use an RCT
design, with data analyses conducted ‘blind’. They should define
the intervention clearly (e.g., diets, physical activity, and behav-
ioural and psychological support), and address separately the
induction (usually 3–6 months) and maintenance (≥12 months)
phases of weight management, potentially employing different
methods within a treatment programme.
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Fig. 4 Percentage of remissions of type 2 diabetes at 12 months after
intervention with different diet types, stratified by study design and risk
of bias. Each dot, with varying shapes to reflect risk of bias, indicates the
data point for each of the studies mentioned in the main text which
provided data in this form at 12 months. The column represents the mean
for the diet type. Remission was defined as either HbA1c < 48 mmol/mol
(<6.5%) or fasting plasma glucose <7 mmol/l, with no glucose-lowering
medication. Total diet replacement programmes included an initial low-
energy formula diet, prescribed for an 8–12 week induction phase,
followed by stepped food re-introduction aimed to achieve energy
balance for weight loss maintenance. VLED advised a 2.9 MJ (700 kcal)
food-based diet for 1 week, then dietary advice for energy intake that
matched for ideal body weight. Very low-carbohydrate ketogenic diet
was ad libitum intake, carbohydrate <30 g/day to achieve ketosis and
3–5 servings of non-starchy vegetables. Usual diet or standard diet inter-
ventions included diabetes education support, but no new diet
intervention
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